ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Silexion Therapeutics Corporation

Silexion Therapeutics Corporation (SLXN)

0,3331
0,1069
(47,26%)
Geschlossen 21 November 10:00PM
0,2799
-0,0532
( -15,97% )
Vor Marktöffnung: 2:01PM

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
0,2799
Gebot
0,2799
Fragen
0,29
Volumen
884.084
0,00 Tagesbereich 0,00
0,207 52-Wochen-Bereich 4,04
Handelsende
0,3331
Handelsbeginn
-
Letzter Handelszeitpunkt
14:01:45
Durchschnittliches Volumen (3 Mio.)
6.160.852
Finanzvolumen
-
VWAP
-

SLXN Neueste Nachrichten

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Latest preclinical studies reveal significant improvements in stability, efficacy, and KRAS targeting range for next-generation siRNA candidate SIL-204 Silexion Therapeutics Corp. (NASDAQ: SLXN...

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

New analysis from Silexion's Phase 2 trial of LODER shows a 56% objective response rate (ORR) and 67% resectability improvement in non-resectable pancreatic cancer Silexion Therapeutics Corp...

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Report covers Silexion Therapeutics (NASDAQ: SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the...

Sielox Reports Second Quarter Sales Growth of 82.5% and Significant Improvement in Financial Performance

RUNNEMEDE, N.J., Aug. 15 /PRNewswire-FirstCall/ -- Sielox, Inc. (OTC:SLXN) (BULLETIN BOARD: SLXN) , a developer, designer and distributor of security solution and industrial vision products...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.039916.6250.240.46580.207398913540.33251217CS
4-0.06-17.6522506620.33990.46580.207104546480.33030347CS
12-1.2001-81.08783783781.481.70.20761608520.49505132CS
26-3.7201-93.002544.040.20755629040.54568337CS
52-3.7201-93.002544.040.20755629040.54568337CS
156-3.7201-93.002544.040.20755629040.54568337CS
260-3.7201-93.002544.040.20755629040.54568337CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
CDTConduit Pharmaceuticals Inc
US$ 0,1976
(114,08%)
38,12M
WORXSCWorx Corporation
US$ 1,93
(96,94%)
21,95M
PETWag Group Company
US$ 0,307
(46,12%)
21,32M
AKTSAkoustis Technologies Inc
US$ 0,1271
(45,92%)
87,28M
ESGROEnstar Group Ltd
US$ 28,00
(40,92%)
29
WSBFWaterstone Financial Inc
US$ 9,00
(-40,98%)
6
TRSTriMas Corporation
US$ 15,62
(-40,79%)
4
BCAXBicara Therapeutics Inc
US$ 11,00
(-40,15%)
316
PYXSPyxis Oncology Inc
US$ 2,40
(-37,17%)
742,33k
XNCRXencor Inc
US$ 15,11
(-36,30%)
7
AKTSAkoustis Technologies Inc
US$ 0,1271
(45,92%)
87,28M
CDTConduit Pharmaceuticals Inc
US$ 0,1976
(114,08%)
38,12M
WORXSCWorx Corporation
US$ 1,93
(96,94%)
21,95M
PETWag Group Company
US$ 0,307
(46,12%)
21,32M
XTKGX3 Holdings Company Ltd
US$ 0,0809
(-10,11%)
11,25M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen